Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

177
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
177
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

166
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
166
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

129
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
129
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

293
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
293
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

233
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
233
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

203
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
203

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From the ground up: Learnings from the development of an innovative statewide adult urgent virtual care service.

Journal of telemedicine and telecare·2026
Same author

Androgen deprivation therapy and kidney function in patients with prostate cancer: an analysis of the RADICAL-PC cohort.

International urology and nephrology·2026
Same author

Towards equitable cancer outcomes for rural and remote communities: reflections, lessons and recommendations.

The Lancet regional health. Western Pacific·2026
Same author

Mavacamten in Obstructive Hypertrophic Cardiomyopathy-A First Australian Experience.

Heart, lung & circulation·2026
Same author

From evidence synthesis to practical tools: Next-user needs for an implementation-ready evidence base to prevent obesity in young children.

Australian and New Zealand journal of public health·2026
Same author

Working Environment in a Virtual Emergency Department: A Cross-Sectional Study.

Emergency medicine Australasia : EMA·2025
Same journal

Diabetes and Risk of Radial Artery Occlusion After Distal Radial Access: Insights From the KODRA Registry.

Heart, lung & circulation·2026
Same journal

Smartwatch-Based Heart Rate Detection in Atrial, Ventricular and Pulseless Arrhythmias.

Heart, lung & circulation·2026
Same journal

Global, Regional and National Burden of Pulmonary Arterial Hypertension in Young and Middle-Aged Adults, 1990-2021, with Projections to 2045.

Heart, lung & circulation·2026
Same journal

2026 Update of the Core Components of Cardiovascular Rehabilitation: A Position Statement From the Australian Cardiovascular Health and Rehabilitation Association (ACRA).

Heart, lung & circulation·2026
Same journal

Outcomes Selected by Pressure Wire in Coronary Artery Revascularisation: The OSCAR Study.

Heart, lung & circulation·2026
Same journal

Coagulopathy in Cardiac Surgery: A Scoping Review of Prothrombin Complex Concentrate.

Heart, lung & circulation·2026
See all related articles

Related Experiment Video

Updated: Dec 31, 2025

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.2K

Myocardial Injury Following Immune Checkpoint Inhibitors: An Australian Experience.

Briella K Egberts1, Rajiv Ananthakrishna2, Rebecca Perry3

  • 1College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia; Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, SA, Australia; South Australian Health and Medical Research Institute, Adelaide, SA, Australia.

Heart, Lung & Circulation
|April 9, 2025
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) may cause subclinical myocardial injury, detected by advanced cardiac imaging, despite low troponin increases. Further research is crucial to understand ICI cardiotoxicity.

Keywords:
Cardiovascular magnetic resonanceEchocardiographyImmune checkpoint inhibitorsMyocardial injuryTroponin I

More Related Videos

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.6K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.5K

Related Experiment Videos

Last Updated: Dec 31, 2025

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.2K
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.6K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.5K

Area of Science:

  • Cardiology
  • Oncology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICIs) are vital cancer therapies.
  • Concerns exist regarding ICI-induced cardiotoxicity, specifically subclinical myocardial injury.
  • Limited local data exists on the incidence of ICI-related cardiac complications.

Purpose of the Study:

  • To assess subclinical myocardial injury in patients receiving ICI therapy without pre-existing cardiovascular disease.
  • Utilize biochemical markers and advanced cardiac imaging to detect myocardial injury.
  • Evaluate the incidence of cardiac complications in this patient population.

Main Methods:

  • Prospective pilot study of 41 patients on ICI therapy.
  • Serial assessments included cardiac troponin I (cTnI), NT-proBNP, echocardiography with strain analysis, and cardiac MRI (CMR) at 6 weeks.
  • A control group (n=10) was included for comparison.

Main Results:

  • Low incidence (2.7%) of significant cTnI increase observed.
  • Significant decrease in left ventricular global longitudinal strain (LV-GLS) in the ICI group.
  • CMR revealed abnormalities in 55% of patients, with 45% showing increased T1 mapping correlating with reduced LV-GLS.
  • Major adverse cardiac events occurred in 45.9% of patients within 1 year.

Conclusions:

  • Subclinical myocardial injury is detectable via advanced cardiac imaging post-ICI initiation, despite low troponin elevation.
  • The findings highlight the need for larger studies to investigate ICI cardiotoxicity prevalence, mechanisms, and clinical impact.